While most men are aware of prostate cancer, many forget to take the steps to have a plan to detect the disease in its early stages.
New York, NY (PRWEB) September 02, 2016
While most men are aware of prostate cancer, many forget to take the steps to have a plan to detect the disease in its early stages. One of the major problems is that there are no symptoms of early stage prostate cancer, so it is critical to understand your risk and talk to your doctor about testing. With the support of celebrities, thought leaders, associations and top industry partners like GenomeDx, this campaign aims to educate and encourage men to create a plan of action to see their doctors and take the proper precautions to prevent, detect early and even treat prostate cancer.
GenomeDx is a commercial stage company that specializes in genomic testing in patients with urologic cancers. The company’s Decipher® Prostate Cancer Classifier is a proven genomic test that analyzes genomic data points from prostate tumors to help identify the right course of treatment for an individual patient. Decipher can be used after a biopsy surgical procedure and/or after prostate removal surgery. It can help guide whether the right path for an individual patient is active surveillance, definitive local therapy, or one or more therapies combined. Genomic testing, like GenomeDx’s Decipher test, has become an increasingly important component in prostate cancer treatment, and facilitates a more personalized, patient-specific approach to treatment.
The print component of “Prostate & Urological Health” is distributed within today’s edition of USA Today in New York, Los Angeles, Chicago and Seattle, with a circulation of approximately 250,000 copies and an estimated readership of 750,000. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here.
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. Its Decipher Genomics Resource Information Database (Decipher GRID) is a large genomics database that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx’s Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and has offices in San Diego, California. Learn more at http://www.GenomeDx.com
Mediaplanet is the leading independent publisher of content-marketing campaigns covering a variety of topics and industries. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers and distributing it within top newspapers and online platforms around the world.